tbuckley/cabot-search huggingface dataset:
Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression
Authors: C. Ngo, T. Grinda, A. Boilève, A. Levy, C. Le Pechoux, L. Haddag, A. Valent, T. Lazure, S. Briand, C. Honoré, M. Faron, O. Mir, R. Bahleda, B. Verret, A. Le Cesne
Journal: Annals of Oncology (2022)
Axonal Length Determines Distinct Homeostatic Phenotypes in Human iPSC Derived Motor Neurons on a Bioengineered Platform (Adv. Healthcare Mater. 10/2022)
Authors: Cathleen Hagemann, Carmen Moreno Gonzalez, Ludovica Guetta, Giulia Tyzack, Ciro Chiappini, Andrea Legati, Rickie Patani, Andrea Serio
Journal: Advanced Healthcare Materials (2022)

Axonal Pathways This cover depicts artistic adaptations of timelapse imaging of human motor axons growing on the bioengineered arrays described in article number 2101817 by Andrea Serio and co-workers, colorcoded to show how the axon elongation proceeds asynchronously over time.
Mitochondrial Micropeptide STMP1 Enhances Mitochondrial Fission to Promote Tumor Metastasis
Authors: Chen Xie, Feng-Yi Wang, Ye Sang, Bin Chen, Jia-Hui Huang, Feng-Jun He, Hui Li, Ying Zhu, Xingguo Liu, Shi-Mei Zhuang, Jian-Hong Fang
Journal: Cancer Research (2022)

Abstract Micropeptides are a recently discovered class of molecules that play vital roles in various cellular processes, including differentiation, proliferation, and apoptosis. Here, we sought to identify cancer-associated micropeptides and to uncover their mechanistic functions. A micropeptide named short transmembrane protein 1 (STMP1) that localizes at the inner mitochondrial membrane was identified to be upregulated in various cancer types and associated with metastasis and recurrence of hepatocellular carcinoma. Both gain- and loss-of-function studies revealed that STMP1 increased dynamin-related protein 1 (DRP1) activation to promote mitochondrial fission and enhanced migration of tumor cells. STMP1 silencing inhibited in vivo tumor metastasis in xenograft mouse models. Overexpression of STMP1 led to redistribution of mitochondria to the leading edge of cells and enhanced lamellipodia formation. Treatment with a DRP1 inhibitor abrogated the promotive effect of STMP1 on mitochondrial fission, lamellipodia formation, and tumor cell migration in vitro and metastasis in vivo. Furthermore, STMP1 interacted with myosin heavy chain 9 (MYH9), the subunit of nonmuscle myosin II, and silencing MYH9 abrogated STMP1-induced DRP1 activation, mitochondrial fission, and cell migration. Collectively, this study identifies STMP1 as a critical regulator of metastasis and a novel unit of the mitochondrial fission protein machinery, providing a potential therapeutic target for treating metastases. Significance: This study identifies the mitochondrial micropeptide STMP1 as a regulator of metastasis that promotes mitochondrial fission and tumor cell migration via DRP1 and MYH9.
Cover Image
Journal: Hepatology (2022)

HepatologyVolume 75, Issue 6 COVER IMAGEFree Access Cover Image First published: 17 May 2022 https://doi.org/10.1002/hep.31951AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume75, Issue6June 2022 RelatedInformation
Purinergic receptors modulators: An emerging pharmacological tool for disease management
Authors: Abid Mahmood, Jamshed Iqbal
Journal: Medicinal Research Reviews (2022)

Abstract Purinergic signaling is mediated through extracellular nucleotides (adenosine 5′‐triphosphate, uridine‐5'‐triphosphate, adenosine diphosphate, uridine‐5'‐diphosphate, and adenosine) that serve as signaling molecules. In the early 1990s, purines and pyrimidine receptors were cloned and characterized drawing the attention of scientists toward this aspect of cellular signaling. This signaling pathway is comprised of four subtypes of adenosine receptors (P1), eight subtypes of G‐coupled protein receptors (P2YRs), and seven subtypes of ligand‐gated ionotropic receptors (P2XRs). In current studies, the pathophysiology and therapeutic potentials of these receptors have been focused on. Various ligands, modulating the functions of purinergic receptors, are in current clinical practices for the treatment of various neurodegenerative disorders and cardiovascular diseases. Moreover, several purinergic receptors ligands are in advanced phases of clinical trials as a remedy for depression, epilepsy, autism, osteoporosis, atherosclerosis, myocardial infarction, diabetes, irritable bowel syndrome, and cancers. In the present study, agonists and antagonists of purinergic receptors have been summarized that may serve as pharmacological tools for drug design and development.
What can the implicit social cognition literature teach us about implicit social cognition?
Authors: Benedek Kurdi, Yarrow Dunham
Journal: Behavioral and Brain Sciences (2022)

Abstract We highlight several sets of findings from the past decade elucidating the relationship between implicit social cognition and real-world inequality: Studies focusing on practical ramifications of implicit social cognition in applied contexts, the relationship between implicit social cognition and consequential real-world outcomes at the level of individuals and geographic units, and convergence between individual-level and corpus-based measures of implicit bias.
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults
Authors: Pavel Sumazin, Tricia L Peters, Stephen F Sarabia, Hyunjae R Kim, Martin Urbicain, Emporia Faith Hollingsworth, Karla R Alvarez, Cintia R Perez, Alice Pozza, Mohammad Javad Najaf Panah, Jessica L Epps, Kathy Scorsone, Barry Zorman, Howard Katzenstein, Allison F O'Neill, Rebecka Meyers, Greg Tiao, Jim Geller, Sarangarajan Ranganathan, Arun A Rangaswami, Sarah E Woodfield, John A Goss, Sanjeev A Vasudevan, Andras Heczey, Angshumoy Roy, Kevin E Fisher, Rita Alaggio, Kalyani R Patel, Milton J Finegold, Dolores H López-Terrada
Journal: Journal of Hepatology (2022)
Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: A 48-week retrospective study
Authors: Shi-Fan Ruan, Liang-Liang Zhang, Zhuo Liu, Ting-Ting Lin, Hai-Qing Wang, Qiu-Yun Xu, Niu Xiang, Bo Cheng, Tao Liu, Herena Y. Ha, Ting Gong, Chao Ji
Journal: Journal of the American Academy of Dermatology (2022)
Prognostic Value of Stress CMR in Symptomatic Patients With Coronary Stenosis on CCTA
Authors: Théo Pezel, Thomas Hovasse, Thierry Lefèvre, Francesca Sanguineti, Thierry Unterseeh, Stéphane Champagne, Hakim Benamer, Antoinette Neylon, Solenn Toupin, Philippe Garot, Bernard Chevalier, Jérôme Garot
Journal: JACC. Cardiovascular imaging (2022)
Odontogenic Fistula
Authors: Mar Luque-Luna, Francesc Alamon-Reig, Daniel Morgado-Carrasco
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Reply to C.-H. Chiang et al and R. Chang et al
Authors: Yu-Sheng Chang, Yu-Chuan Shen, Jin-Hua Chen, Chi-Ching Chang
Journal: Journal of Clinical Oncology (2022)

We appreciate the thoughtful comments from Chiang et al 1 and Chang et al 2 regarding the methodologies of our study. 3The study has limitations inherent in the retrospective cohort design.However, for this topic, we believed this design was pretty suitable because a prospective study is not feasible.Minimizing possible bias by optimizing the study method is vital.However, the modification of methodology was a trade-off.In general, we agreed most points in the two letters.Nevertheless, further analyses were not possible because the study project has already ended in 2020.
Tacrolimus Prevents Mechanical and Humoral Alterations in Brain Death–induced Lung Injury in Pigs
Authors: Asmae Belhaj, Laurence Dewachter, Emeline Hupkens, Myriam Remmelink, Laurence Galanti, Sandrine Rorive, Christian Melot, Robert Naeije, Benoît Rondelet
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: Donor brain death-induced lung injury may compromise graft function after transplantation. Establishing strategies to attenuate lung damage remains a challenge because the underlying mechanisms remain uncertain. Objectives: The effects of tacrolimus pretreatment were evaluated in an experimental model of brain death-induced lung injury. Methods: Brain death was induced by slow intracranial infusion of blood in anesthetized pigs after randomization to tacrolimus (orally administered at 0.25 mg. kg-1 BID the day before the experiment and intravenously at 0.05 mg. kg-1 one hour before the experiment; n=8) or placebo (n=9) pretreatment. Hemodynamic measurements were performed 1, 3, 5 and 7 hours after brain death. After euthanasia of the animals, lung tissue was sampled for pathobiological and histological analysis, including lung injury scoring (LIS). Measurements and main results: Tacrolimus pretreatment prevented increases in pulmonary artery pressure, pulmonary vascular resistance and pulmonary capillary pressure and decreases in systemic artery pressure and thermodilution cardiac output associated with brain death. After brain death, the ratio of the partial arterial O2 pressure to the inspired O2 fraction (PaO2/FiO2) decreased, which was prevented by tacrolimus. Tacrolimus pretreatment prevented increases in the interleukin (IL)-6-to-IL-10 ratio, vascular cell adhesion molecule-1, circulating levels of IL-1β, IL-6-to-IL-10 ratio and glycocalyx-derived molecules. Tacrolimus partially decreased apoptosis [Bax-to-Bcl2 ratio (p=0.07) and the number of apoptotic cells in the lungs (p<0.05)] but failed to improve LIS. Conclusions: Immunomodulation through tacrolimus pretreatment prevented pulmonary capillary hypertension as well as the activation of inflammatory and apoptotic processes in the lungs after brain death; however, LIS did not improve.
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
Authors: Adam J. Kanack, Antonios Bayas, Gemlyn George, Mouhamed Yazan Abou-Ismail, Bandana Singh, Mindy C. Kohlhagen, Noah P. Splinter, Monika Christ, Markus Naumann, Karen A. Moser, Kristi J. Smock, Alison Grazioli, Renren Wen, Demin Wang, David L. Murray, Anand Padmanabhan
Journal: Blood (2022)
Reduced Heart Failure and Mortality in Patients Receiving Statin Therapy Before Initial Acute Coronary Syndrome
Authors: Raffaele Bugiardini, Jinsung Yoon, Guiomar Mendieta, Sasko Kedev, Marija Zdravkovic, Zorana Vasiljevic, Davor Miličić, Olivia Manfrini, Mihaela van der Schaar, Chris P. Gale, Maria Bergami, Lina Badimon, Edina Cenko
Journal: Journal of the American College of Cardiology (2022)
More than a Marker: Arginase-1 in Kidney Repair
Authors: Sibylle von Vietinghoff, Roland Schmitt
Journal: Journal of the American Society of Nephrology (2022)

AKI is an important risk factor for CKD. There are many unanswered questions regarding the role of specific cell types and molecular pathways in the so-called AKI-CKD transition. Too little is known about targetable factors that determine whether successful repair or a maladaptative process ensues
Engineered Cell‐Secreted Extracellular Matrix Modulates Cell Spheroid Mechanosensing and Amplifies Their Response to Inductive Cues for the Formation of Mineralized Tissues (Adv. Healthcare Mater. 10/2022)
Authors: Tomas Gonzalez‐Fernandez, Alejandro J. Tenorio, Augustine M. Saiz Jr, J. Kent Leach
Journal: Advanced Healthcare Materials (2022)

Mesenchymal Stromal Cells In article number 2102337 by J. Kent Leach and co-workers, an engineered cell-secreted extracellular matrix (ECM) is incorporated into mesenchymal stromal cell (MSC) spheroids to promote cell–cell and cell–matrix interactions and enhance MSC survival and differentiation. Activation of YAP through integrin binding to the incorporated ECM promotes MSC proliferation and osteogenic differentiation, highlighting the therapeutic potential of ECM-loaded spheroids as building blocks for bone repair.
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533
Authors: Laura M. Madanat-Harjuoja, Lindsay A. Renfro, Kelly Klega, Brett Tornwall, Aaron R. Thorner, Anwesha Nag, David Dix, Jeffrey S. Dome, Lisa R. Diller, Conrad V. Fernandez, Elizabeth A. Mullen, Brian D. Crompton
Journal: Journal of Clinical Oncology (2022)

The utility of circulating tumor DNA (ctDNA) analyses has not been established in the risk stratification of Wilms tumor (WT). We evaluated the detection of ctDNA and selected risk markers in the serum and urine of patients with WT and compared findings with those of matched diagnostic tumor samples.
RNA2Immune: A Database of Experimentally Supported Data Linking Non-Coding RNA Regulation to the Immune System
Authors: Jianjian Wang, Shuang Li, Tianfeng Wang, Si Xu, Xu Wang, Xiaotong Kong, Xiaoyu Lu, Huixue Zhang, Lifang Li, Meng Feng, Shangwei Ning, Lihua Wang
Journal: Genomics Proteomics & Bioinformatics (2022)

Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have emerged as important regulators of the immune system and are involved in the control of immune cell biology, disease pathogenesis, as well as vaccine responses. A repository of ncRNA-immune associations will facilitate our understanding of ncRNA-dependent mechanisms in the immune system and advance the development of therapeutics and prevention for immune disorders. Here, we describe a comprehensive database, RNA2Immune, which aims to provide a high-quality resource of experimentally supported database linking ncRNA regulatory mechanisms to immune cell function, immune disease, cancer immunology, and vaccines. The current version of RNA2Immune documents 50,433 immune-ncRNA associations in 42 host species, including (1) 6690 ncRNA associations with immune functions involving 31 immune cell types; (2) 38,672 ncRNA associations with 348 immune diseases; (3) 4833 ncRNA associations with cancer immunology; and (4) 238 ncRNA associations with vaccine responses involving 26 vaccine types targeting 22 diseases. RNA2Immune provides a user-friendly interface for browsing, searching, and downloading ncRNA-immune system associations. Collectively, RNA2Immune provides important information about how ncRNAs influence immune cell function, how dysregulation of these ncRNAs leads to pathological consequences (immune diseases and cancers), and how ncRNAs affect immune responses to vaccines. RNA2Immune is available at http://bio-bigdata.hrbmu.edu.cn/rna2immune/home.jsp.
Incorrect Spelling of Author Name
Authors: Tarek Taifour, Ezekiel Emanuel, David Michaels, Rick Bright
Journal: JAMA (2022)

Vibhu Parcha, MD; Gargya Malla, MD, MPH, PhD; Marguerite R. Irvin, PhD; Nicole D. Armstrong, PhD; Suzanne E. Judd, PhD; Leslie A. Lange, PhD; Mathew S. Maurer, MD; Emily B. Levitan, ScD; Parag Goyal, MD, MSc; Garima Arora, MD; Pankaj Arora, MD
Multinational landscape of health app policy: toward regulatory consensus on digital health
Authors: James A. Diao, Kaushik P. Venkatesh, Marium M. Raza, Joseph C. Kvedar
Journal: npj Digital Medicine (2022)

Due to its enormous capacity for benefit, harm, and cost, health care is among the most tightly regulated industries in the world. But with the rise of smartphones, an explosion of direct-to-consumer mobile health applications has challenged the role of centralized gatekeepers. As interest in health apps continue to climb, national regulatory bodies have turned their attention toward strategies to protect consumers from apps that mine and sell health data, recommend unsafe practices, or simply do not work as advertised. To characterize the current state and outlook of these efforts, Essén and colleagues map the nascent landscape of national health app policies and raise several considerations for cross-border collaboration. Strategies to increase transparency, organize app marketplaces, and monitor existing apps are needed to ensure that the global wave of new digital health tools fulfills its promise to improve health at scale.
Assessment of Latent Subgroups With Suicidal Ideation and Suicidal Behavior Among Gun Owners and Non–Gun Owners in the US
Authors: Craig J. Bryan, AnnaBelle O. Bryan, Heather M. Wastler, Lauren R. Khazem, Ennio Ammendola, Justin C. Baker, Edwin Szeto, Jeffrey Tabares, Christina R. Bauder
Journal: JAMA Network Open (2022)

Firearm ownership is associated with increased risk for suicide.
Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma
Authors: Maria Cristina Pirosa, Sven Borchmann, Fabrice Jardin, Gianluca Gaidano, Davide Rossi
Journal: HemaSphere (2022)

The rapid evolution of genomic technologies over the last years has led to the development of different methods for the detection, measurement and analysis of cell-free DNA fragments (cfDNA) which are shed into the bloodstream by apoptotic cells and circulate at a low concentration in plasma. In cancer patients, the proportion of tumor-derived cfDNA is defined as circulating tumor DNA. This analysis, commonly known as liquid biopsy, allows to access tumor DNA through a simple blood sampling and therefore without the need of an invasive tissue biopsy. For this reason, this tool may have several clinical applications in terms of diagnosis, prognosis, and monitoring of minimal residual disease. However, there are still several critical issues that need to be resolved. In this review, we will discuss some of the controversies around this method and its potential clinical applications.
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
Authors: Jia-Tao Zhang, Si-Yang Liu, Wei Gao, Si-Yang Maggie Liu, Hong-Hong Yan, Liyan Ji, Yu Chen, Yuhua Gong, Hong-Lian Lu, Jun-Tao Lin, Kai Yin, Ben-Yuan Jiang, Qiang Nie, Ri-Qiang Liao, Song Dong, Yanfang Guan, Pingping Dai, Xu-Chao Zhang, Jin-Ji Yang, Hai-Yan Tu, Xuefeng Xia, Xin Yi, Qing Zhou, Wen-Zhao Zhong, Xue-Ning Yang, Yi-Long Wu
Journal: Cancer Discovery (2022)

The efficacy and potential limitations of molecular residual disease (MRD) detection urgently need to be fully elucidated in a larger population of non-small cell lung cancer (NSCLC). We enrolled 261 patients with stages I to III NSCLC who underwent definitive surgery, and 913 peripheral blood samples were successfully detected by MRD assay. Within the population, only six patients (3.2%) with longitudinal undetectable MRD recurred, resulting in a negative predictive value of 96.8%. Longitudinal undetectable MRD may define the patients who were cured. The peak risk of developing detectable MRD was approximately 18 months after landmark detection. Correspondingly, the positive predictive value of longitudinal detectable MRD was 89.1%, with a median lead time of 3.4 months. However, brain-only recurrence was less commonly detected by MRD (n = 1/5, 20%). Further subgroup analyses revealed that patients with undetectable MRD might not benefit from adjuvant therapy. Together, these results expound the value of MRD in NSCLC. This study confirms the prognostic value of MRD detection in patients with NSCLC after definitive surgery, especially in those with longitudinal undetectable MRD, which might represent the potentially cured population regardless of stage and adjuvant therapy. Moreover, the risk of developing detectable MRD decreased stepwise after 18 months since landmark detection. This article is highlighted in the In This Issue feature, p. 1599.
Abstract A015: Inferring phylogenetic trees based on copy number aberrations from methylation array
Authors: Chuling Ding, Javier Herrero
Journal: Cancer Research (2022)

Abstract Background: The development of methylation array platforms has allowed large scale studies on cancer epigenomes. Apart from intended analyses on methylation patterns, it is also possible to infer copy number profiles by leveraging the signal from methylation array data. To disentangle complex mixtures of phylogenetically related clones, it is best to jointly analyze different samples (different regions, timepoints, etc.) from the same tumor. However, current methods for studying copy number aberrations (CNAs) from methylation arrays consider tumor samples independently. In this project, we introduce Multi-Sample EPIC Phylogenetic Reconstruction (MultiSEPhyR), aiming to investigate the copy number profiles and clonal compositions from multi-sample methylation array data. Material and methods: As part of the GCGR (Glioma Cellular Genetic Resource; gcgr.org.uk) project, we analyze 53 samples from 26 cases with multiple methylation array data of primary glioblastomas, tumor-derived cell lines and xenograft re-derived cell lines. Copy Number Aberrations (CNAs) called from the methylation array data are validated using WGS data from a subset of the cohort. By jointly clustering the segmented LogR ratios from related samples, we can define tumor clones based on clustered CNA events. We use a two-step approach, where we firstly identify clonal events to obtain sample purity and tumor ploidy and use these values to subsequently infer the copy number state and the clonality of the remaining events. Results and Discussions: On a simulated dataset, MultiSEPhyR could accurately estimate sample purity and identify both clonal and sub-clonal CNA events. We then apply our method on GCGR dataset and show similar extent of intra-tumor heterogeneity in primary glioblastomas and derived cell lines. We also investigate clonal dynamics in each case. In the cell lines, while the heterogeneity is well captured, some sub-clonal CNA events may exhibit significantly different clonality compared to the primary glioblastomas. For example, we observe a clonal expansion of the clones harboring a deletion in chromosome 6 in xenograft re-derived cell lines. Conclusion We present a systematic way to call CNAs and resolve clonal compositions from methylation array data, leading to a cost-efficient way to study tumor evolution. Citation Format: Chuling Ding, Javier Herrero. Inferring phylogenetic trees based on copy number aberrations from methylation array [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A015.